Genotype-based risk and pharmacogenetic sampling in clinical trials.
Ontology highlight
ABSTRACT: A number of recent genome-wide association (GWA) studies have identified unequivocal statistical associations between inherited genetic variations, mostly single-nucleotide polymorphisms (SNPs), and common complex diseases such as diabetes, cardiovascular disease, and obesity. Genotyping individuals for these variations has the potential to help redefine how pharmacologic agents undergo clinical development. By identifying carriers of known genomic variants that contribute to susceptibility, a high-risk population can be defined, as well as individuals with potential for a better response to a drug. We evaluated the potential utility that selecting individuals for a trial on the basis of genotypes identified in contemporary GWA studies would have had on recently described clinical trials.
SUBMITTER: Schork NJ
PROVIDER: S-EPMC2892229 | biostudies-literature | 2010 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA